Saskia Meyer

Scientist T cell Immunotherapy / Process development at Faculty of Medicine, University of Oslo
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Oslo, Oslo, Norway, NO
Languages
  • English Full professional proficiency
  • German Native or bilingual proficiency
  • Dutch Elementary proficiency
  • French Elementary proficiency
  • Spanish Elementary proficiency
Skills

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • ADVANCE 5-Day Workshop for ATMP Developers
    ADVANCE ATMP Training Programme
    Jul, 2021
    - Oct, 2024

Experience

  • Det medisinske fakultet UiO
    • Norway
    • Higher Education
    • 1 - 100 Employee
    • Scientist T cell Immunotherapy / Process development
      • Jan 2021 - Present

      Driving the early-phase implementation of TCR mediated T cell therapy into the clinics by being responsible for the translation of research laboratory methods to pre-GMP settings, eventually allowing production of gene-modified T cells under GMP conditions. My research includes the evaluation of potential TCR candidates targeting cancer-specific antigens. Driving the early-phase implementation of TCR mediated T cell therapy into the clinics by being responsible for the translation of research laboratory methods to pre-GMP settings, eventually allowing production of gene-modified T cells under GMP conditions. My research includes the evaluation of potential TCR candidates targeting cancer-specific antigens.

  • Radiumhospitalet Oslo, Norway
    • Oslo Area, Norway
    • Postdoctoral Fellow
      • Feb 2017 - Jan 2021

      We are interested in the identification of new T cell receptors targeting cancer associated antigens which can be used for the treatment of cancer patients. We set up a functional screen for the isolation of reactive T cells recognizing the antigen of interest in the T cell pool of healthy volunteers. We are interested in the identification of new T cell receptors targeting cancer associated antigens which can be used for the treatment of cancer patients. We set up a functional screen for the isolation of reactive T cells recognizing the antigen of interest in the T cell pool of healthy volunteers.

  • UMC Utrecht
    • Netherlands
    • Hospitals and Health Care
    • 700 & Above Employee
    • PhD Candidate
      • Nov 2011 - Sep 2016

      The group is interested in investigating the potential of IgA antibodies in cancer immunotherapy. Project 1: In vivo studies in mice are complicated by the short half-life of IgA antibodies. It has been shown before that IgA antibodies are cleared from circulation because of two main reasons: (1) binding to sugar receptors expressed in in liver, and (2) lack of binding to the neonatal Fc receptor, which is responsible for the long half-life of e.g. IgG antibodies and albumin. We therefore applied two major strategies to extend the in vivo half-life: (1) glyco-engineering, and (2) protein-engineering (indirect targeting of the neonatal Fc receptor by attaching an albumin binding domain to the IgA molecule). These antibodies produced by ourselves or in collaboration were tested functionally in a diverse panel of in vitro assays. Both strategies resulted in a significant increase of the in vivo half-life and serum exposure. We eventually tested their in vivo potential in mice and the extended in vivo half-life allowed us to optimizing the treatment regimen (less frequent injections). Project 2: IgG antibodies for the treatment of solid and hematological cancers is available. Hematological tumor cells predominantly reside in the blood stream Here, neutrophils are abundantly present. These effector cells are expressing the Fc alpha receptor recognized by the Fc tail of IgA antibodies and have been shown before to efficiently lyse tumor cells in vitro. Therefore, we developed a panel of unique mIgG-CD20 mAbs which were characterized intensively in vitro (e.g. ADCC, CDC, apoptosis induction, binding, epitope, in vivo). The variable domains of promising candidates were cloned into the IgG1 and IgA backbone, the antibodies produced in house and preliminary in vitro and in vivo results are promising. Show less

  • Genmab
    • Denmark
    • Biotechnology Research
    • 700 & Above Employee
    • Intern
      • Mar 2011 - Aug 2011

      Setting up a method for ‘High resolution epitope mapping for antibody discovery’ Setting up a method for ‘High resolution epitope mapping for antibody discovery’

  • DKFZ German Cancer Research Center
    • Germany
    • Research Services
    • 700 & Above Employee
    • Intern
      • Nov 2009 - Feb 2010

      Generation and evaluation of recombinant bispecific antibodies against non-Hodgkin’s Lymphoma Generation and evaluation of recombinant bispecific antibodies against non-Hodgkin’s Lymphoma

  • The Children's Hospital at Westmead, Sydney (Australia)
    • Westmead, Sydney, Australia
    • Intern
      • Aug 2008 - Jan 2009

      Analyse how the HEF1 protein influences microtubule dynamics by applying live imaging, western blotting and epifluorescence microscopy Analyse how the HEF1 protein influences microtubule dynamics by applying live imaging, western blotting and epifluorescence microscopy

Education

  • Hochschule Mannheim
    Master of Science (M.Sc.), Biotechology
    2010 - 2011
  • Hochschule Mannheim
    Bachelor of Science (B.Sc.), Biotechnology
    2006 - 2010
  • Carl-Benz Gymnasium Ladenburg (Germany)
    University entree qualification (Abitur)
    1997 - 2006

Community

You need to have a working account to view this content. Click here to join now